I've been with CHTP prior to their FDA AdCom minutes fiasco where the reviewer was unduly harsh with Northera. After the FDA Panel voted 7-4-1, I didn't expect a 2 year delay.
Running trials to check for durability in older patients is difficult as their memory isn't as sharp and their ability to compare 'dizziness' from pre-treatment and while on treatment is tricky.